Steenbruggen TG, Steggink LC, Seynaeve CM, et al. - A randomized control trial was conducted to ascertain 20-year efficacy and safety outcomes of a large trial of adjuvant high-dose chemotherapy (HDCT) vs conventional-dose chemotherapy (CDCT) for individuals with stage III breast cancer. Between August 1, 1993, to July 31, 1999, researchers used data from a randomized phase 3 multicenter clinical trial including a total of 885 women younger than 56 years with breast cancer. Among 885 women (mean [SD] age, 44.5 [6.6] years), 442 were assigned randomly to receive HDCT, and 443 were randomized to receive CDCT. There was no long-term survival benefit by high-dose chemotherapy in unselected individuals with stage III breast cancer but did provide improved overall survival in very high-risk individuals (ie, with ≥10 involved axillary lymph nodes). The results indicated that high-dose chemotherapy did not influence long-term risk of a second malignant neoplasm or major cardiovascular events.